![prasanth reddy prasanth reddy](https://www.vaidam.com/sites/default/files/dr-prasanth-reddy-min_0.jpg)
This press release contains forward-looking statements, including but not limited to statements with respect to the Company’s future operations, expansion of offerings and capabilities, and opportunities for future growth. Learn about Covance by Labcorp at and Labcorp at or follow us on LinkedIn and Twitter Statement Regarding Forward-Looking Statements Labcorp (NYSE: LH) reported revenue of $11.5 billion in FY2019. With over 70,000 employees, we serve clients in more than 100 countries. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. He received his doctorate in cell biology from the University of Michigan in Ann Arbor and completed his post-doctoral training in molecular biology at Princeton University. He previously worked as the deputy head for the oncology biomarkers and imaging group for Novartis Oncology and spent nine years at Merck, where he led the basic research molecular profiling group and Merck’s oncology biomarkers efforts. Phillips also served as vice president and head of precision medicine at Pfizer, and prior to that, at Regeneron Pharmaceuticals, he was head of precision medicine for all therapeutic areas and he co-founded the Regeneron Genetics Center.
![prasanth reddy prasanth reddy](https://d1k13df5m14swc.cloudfront.net/photos/Dr-Prashanth-Reddy-MD-295685-circle_large__v1__.png)
He joins Labcorp from Daiichi-Sankyo, where he was vice president and head of translational science, and where he oversaw companion diagnostics efforts. Phillips is a scientist with many years of experience in biomarkers, patient selection, and development of drug-linked diagnostics, with a focus on oncology. Additionally, he is a fellow of the American College of Physicians and is a Certified Physician Executive.ĭr. Reddy obtained a master’s degree in public health through a National Institutes of Health Clinical Research Curriculum Award (K30) and is an alumnus of Harvard Business School.
![prasanth reddy prasanth reddy](https://i.ytimg.com/vi/9rOJ6NWZlqM/maxresdefault.jpg)
Reddy earned a bachelor’s degree in microbiology and psychology from Kansas State University, and he earned his medical degree from the University of Kansas Medical Center, where he also completed his internal medicine residency and clinical hematology and oncology fellowship. Reddy worked as a national leader developing oncology service line treatment pathways at the Adventist Health System. He is triple board-certified in internal medicine, medical oncology, and hematology, and he practiced medicine and served in leadership positions for more than 10 years in various clinical settings including academia, private practice, and managed care. Reddy was most recently vice president of medical affairs at Foundation Medicine, Inc. We will continue to expand our capabilities in oncology, and we are excited to build a world-class leadership team in this area.”ĭr. “We are proud to be a leader in advancing science and innovation in cancer diagnosis and discovering new therapies to serve pharmaceutical companies, oncologists, researchers, and patients. Paul Kirchgraber, CEO, Labcorp Drug Development. Phillips to our oncology leadership team,” said Dr. The enterprise oncology unit will utilize the combined assets of the drug development and diagnostics businesses, leveraging biomarkers and companion diagnostics to help bring the right treatment to the right patient at the right time. Phillips will be vice president and head of enterprise oncology science. Reddy will serve as senior vice president and enterprise oncology head of the company’s enterprise oncology unit, and Dr. BURLINGTON, N.C.-( BUSINESS WIRE)-Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointments of Prasanth Reddy, MD, MPH, and Robert Phillips, PhD, to its oncology team, advancing Labcorp’s leadership position and capabilities in cancer diagnosis, treatment, and drug development.ĭr.